GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » ROE %

Vycor Medical (Vycor Medical) ROE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vycor Medical's annualized net income for the quarter that ended in Mar. 2024 was $-0.12 Mil. Vycor Medical's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-3.42 Mil. Therefore, Vycor Medical's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Vycor Medical's ROE % or its related term are showing as below:

VYCO's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.54
* Ranked among companies with meaningful ROE % only.

Vycor Medical ROE % Historical Data

The historical data trend for Vycor Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vycor Medical ROE % Chart

Vycor Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vycor Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity Negative Equity - - -

Competitive Comparison of Vycor Medical's ROE %

For the Medical Devices subindustry, Vycor Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vycor Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vycor Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Vycor Medical's ROE % falls into.



Vycor Medical ROE % Calculation

Vycor Medical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-0.07/( (-2.941+-3.325)/ 2 )
=-0.07/-3.133
=N/A %

Vycor Medical's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-0.124/( (-3.325+-3.518)/ 2 )
=-0.124/-3.4215
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Vycor Medical  (OTCPK:VYCO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-0.124/-3.4215
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.124 / 1.348)*(1.348 / 0.9805)*(0.9805 / -3.4215)
=Net Margin %*Asset Turnover*Equity Multiplier
=-9.2 %*1.3748*N/A
=ROA %*Equity Multiplier
=-12.65 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-0.124/-3.4215
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.124 / -0.124) * (-0.124 / -0.04) * (-0.04 / 1.348) * (1.348 / 0.9805) * (0.9805 / -3.4215)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 3.1 * -2.97 % * 1.3748 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Vycor Medical ROE % Related Terms

Thank you for viewing the detailed overview of Vycor Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vycor Medical (Vycor Medical) Business Description

Traded in Other Exchanges
N/A
Address
951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487
Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.
Executives
David Cantor director, officer: President 1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell director, officer: Chairman ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou director, 10 percent owner, officer: Chief Executive Officer C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush director C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti director C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd 10 percent owner PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical (Vycor Medical) Headlines